5-溴吲哚酚二醋酸盐 | 33588-54-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-溴吲哚酚二醋酸盐
• 中文别名: N-乙酰基5溴吲哚3乙酸酯；5-溴吲哚酚二乙酸酯；1-[3-(乙酰氧基)-5-溴-1H-吲哚-1-基]酮；5-溴吲哚酚二醋酸酯；5-溴羟基吲哚二乙酸酯
• 英文名称: 5-bromoindoxyl diacetate
• 英文别名: 5-bromo-O,N-acetylindoxyl；1-acetyl-5-bromo-3-indolyl acetate；5-Brom-O,N-diacetylindoxyl；1-Acetyl-5-bromo-1H-indol-3-yl acetate；(1-acetyl-5-bromoindol-3-yl) acetate
• CAS: 33588-54-4
• 化学式: C₁₂H₁₀BrNO₃
• mdl: MFCD00005799
• 分子量: 296.12
• InChiKey: XJRIDJAGAYGJCK-UHFFFAOYSA-N

物化性质

• 熔点：
  125-128 °C(lit.)
• 沸点：
  395.7±22.0 °C(Predicted)
• 密度：
  1.6469 (rough estimate)
• 稳定性/保质期：
  如果按照规定使用和储存，则不会发生分解，目前没有发现已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  48.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Name:	5-Bromoindoxyl Diacetate 99% Material Safety Data Sheet
Synonym:	None known
CAS:	33588-54-4

Section 1 - Chemical Product MSDS Name:5-Bromoindoxyl Diacetate 99% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
33588-54-4	5-Bromoindoxyl Diacetate	99	251-584-0

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 33588-54-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: yellow
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 125-128C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H10BrNO3
Molecular Weight: 296.11

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, irritating and toxic fumes and gases, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 33588-54-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Bromoindoxyl Diacetate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 33588-54-4: No information available.
Canada
CAS# 33588-54-4 is listed on Canada's DSL List.
CAS# 33588-54-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 33588-54-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴吲哚酚二醋酸盐 在 sodium hydroxide 、 水 作用下， 生成 5-溴代-3-羟基吲哚乙酸酯
  参考文献：
  名称：

  Holt; Sadler, Proceedings of the Royal Society of London. Series B, Biological sciences, 1958, vol. 148, p. 481,491,493

  摘要：

  DOI：
• 作为产物：
  描述：

  2,5-二溴苯甲酸 在 乙酸酐 、 potassium carbonate 、 potassium hydroxide 作用下， 生成 5-溴吲哚酚二醋酸盐
  参考文献：
  名称：

  基于吲哚酚的不对称3,3'-双吲哚合成策略

  摘要：

  已知3,3'-双吲哚是生物活性天然产物，药物和功能材料中的重要结构基序。本文中，建立了基于吲哚的新颖方法，用于从吲哚和吲哚合成不对称的3,3'-联吲哚。该方法产生所需产物的中等至极好的产率（24个实施例，产率高达98％）。本方法的特征在于广泛的底物范围，操作简单，高原子经济性以及利用无毒且廉价的分子碘作为催化剂。简便的克级合成已证明了该方法的适用性。

  DOI：

  10.1016/j.tetlet.2016.10.099

文献信息

• Synthesis and Evaluation of Cryptolepine Analogues for Their Potential as New Antimalarial Agents
  作者：Colin W. Wright、Jonathan Addae-Kyereme、Anthony G. Breen、John E. Brown、Marlene F. Cox、Simon L. Croft、Yaman Gökçek、Howard Kendrick、Roger M. Phillips、Pamela L. Pollet

  DOI：10.1021/jm010929+

  日期：2001.9.1

  The indoloquinoline alkaloid cryptolepine 1 has potent in vitro antiplasmodial activity, but it is also a DNA intercalator with cytotoxic properties. We have shown that the antiplasmodial mechanism of 1 is likely to be due, at least in part, to a chloroquine-like action that does not depend on intercalation into DNA. A number of substituted analogues of 1 have been prepared that have potent activities

  吲哚喹啉碱生物碱1具有强大的体外抗血浆活性，但它也是具有细胞毒性的DNA嵌入剂。我们已经表明1的抗疟原虫机制可能至少部分是由于不依赖于插入DNA的类似氯喹的作用。已经制备了许多取代的类似物1，它们对恶性疟原虫的氯喹敏感和耐氯喹菌株均具有有效的活性，并且与氯喹共同具有抑制无细胞系统中β-血红素形成的作用。几种化合物还对小鼠伯氏疟原虫表现出活性，最有效的是2,7-二溴隐油菜素8，与未经处理的感染对照相比，在剂量为12.5 mg kg（-1）day（-1）时，其寄生虫抑制率达89％。 ip。
• Synthesis of Some Cryptolepine Analogues, Assessment of Their Antimalarial and Cytotoxic Activities, and Consideration of Their Antimalarial Mode of Action
  作者：Onyeka Onyeibor、Simon L. Croft、Hilary I. Dodson、Mohammad Feiz-Haddad、Howard Kendrick、Nicola J. Millington、Silvia Parapini、Roger M. Phillips、Scott Seville、Steven D. Shnyder、Donatella Taramelli、Colin W. Wright

  DOI：10.1021/jm040893w

  日期：2005.4.1

  seen (ED(90) = 21.6 mg kg(-1) day(-1)). The antimalarial mode of action of 1 appears to be similar to that of chloroquine and involves the inhibition of hemozoin formation. A number of analogues were assessed for their effects on the inhibition of beta-hematin (hemozoin) formation, and the results were compared with their antiplasmodial activities having taken account of their predicted accumulation into

  已经合成了一系列隐血藤碱（1）的类似物，并对其体外抗血浆和细胞毒性特性进行了评估。几种化合物（11a，11k-m，11o，13）对恶性疟原虫（K1株）的IC（50）值<0.1μM，比1的低5-10倍，但它们的细胞毒性仅为2-4 1倍于1倍于喹啉环的卤素和1个吲哚环的卤素或硝基的化合物具有增强的抗血浆活性。在感染伯氏疟原虫的小鼠中，剂量为25 mg kg（-1）的7-溴-2-氯（11k）和2-溴-7-硝基（13）衍生物1抑制寄生虫血症> 90％ （-1）对小鼠无明显毒性。2,7-Dibromocryptolepine（15）在几个剂量水平下进行了评估，并观察到了寄生虫血症的剂量依赖性抑制作用（ED（90）= 21。6 mg kg（-1）天（-1））。1的抗疟疾作用模式似乎与氯喹相似，并且涉及抑制血zo素的形成。评估了许多类似物对β-血凝素（血红蛋白）形成的抑制作用，并考虑到它们在酸性寄生虫食
• AZAINDOLE-INDOLE COUPLED DERIVATIVES, PREPARATION METHODS AND USES THEREOF
  申请人：Cheng Jingcai

  公开号：US20100137356A1

  公开（公告）日：2010-06-03

  A novel class of azaindole-indole coupled derivatives, their preparation methods, pharmaceutical compositions containing the same and the uses thereof. The common structural feature of these derivatives is that they are coupled by azaindole and indole bi-molecule at different positions, forming extended pi-conjugated systems. Such derivatives inhibited cell growth and proliferation by various mechanisms. The present compounds have improved solubility, increased bioavailability, and thus have enhanced drug actions, and reduced medical dosages and undesired responses.

  一种新型的氮杂吲哚-吲哚偶联衍生物类，其制备方法、含有这些衍生物的药物组合物以及它们的用途。这些衍生物的共同结构特征是它们通过氮杂吲哚和吲哚双分子在不同位置偶联，形成扩展的π共轭系统。这些衍生物通过多种机制抑制细胞生长和增殖。目前的化合物具有改善的溶解性、增加的生物利用度，因此具有增强的药物作用，减少了药物剂量和不良反应。
• Synthesis and evaluation of analogues of 10H-indolo[3,2-b]quinoline as G-quadruplex stabilising ligands and potential inhibitors of the enzyme telomerase
  作者：B�rang�re Guyen、Christoph M. Schultes、Pascale Hazel、John Mann、Stephen Neidle

  DOI：10.1039/b316055f

  日期：——

  We report here the synthesis and evaluation for telomerase-inhibitory and quadruplex DNA binding properties of several rationally-designed quindoline analogues, substituted at the 2- and 7- positions. The ability of these compounds to interact with and stabilise an intramolecular G-quadruplex DNA against increases in temperature was evaluated by a fluorescence-based (FRET) melting assay. The resulting

  我们在这里报告的合成和评估的几个合理设计的喹啉类似物，在2和7位取代的端粒酶抑制和四链体DNA结合特性。通过基于荧光的（FRET）熔解测定法评估了这些化合物与分子内G-四链体DNA相互作用并稳定其抵抗温度升高的能力。如在体外端粒酶TRAP测定中所测量的，发现所得的T（m）值与其抑制端粒酶的能力相关。通过分子建模方法模拟了具有四链DNA分子结构的多种化合物之间的相互作用。结论是这类化合物代表了一种新的化学类型，适合作为端粒酶抑制剂的进一步开发。
• Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer
  作者：Zhuoxian Cao、Fenfen Yang、Jie Wang、Zhicheng Gu、Shuxian Lin、Pan Wang、Jianxiong An、Ting Liu、Yan Li、Yongjun Li、Hening Lin、Yonglong Zhao、Bin He

  DOI：10.1021/acs.jmedchem.1c01311

  日期：2021.10.28

  To utilize the unique scaffold of a natural product indirubin, we herein adopted the strategy of combined pharmacophores to design and synthesize a series of novel indirubin derivatives as dual inhibitors against cyclin-dependent kinase (CDK) and histone deacetylase (HDAC). Among them, the lead compound 8b with remarkable CDK2/4/6 and HDAC6 inhibitory activity of IC50 = 60.9 ± 2.9, 276 ± 22.3, 27.2

  为了利用天然产物靛玉红的独特支架，我们在此采用组合药效团的策略来设计和合成一系列新型靛玉红衍生物，作为针对细胞周期蛋白依赖性激酶 (CDK) 和组蛋白脱乙酰酶 (HDAC) 的双重抑制剂。其中，先导化合物8b具有显着的CDK2/4/6和HDAC6抑制活性，IC 50 = 60.9 ± 2.9、276 ± 22.3、27.2 ± 4.2和128.6 ± 0.4 nM，可有效诱导细胞凋亡和S期在几种癌细胞系中停滞。特别是化合物8b可以通过 Mcl-1/XIAP/PARP 轴阻止非小细胞肺癌细胞系 (A549) 的增殖，这与 HDAC 抑制剂和 CDK 抑制剂联合药物的独特作用模式一致。在 A549 静电复印机模型中，化合物8b显示出与其双重抑制相关的显着抗肿瘤功效。我们的数据表明，化合物8b作为单一药物可能是与 CDK 和 HDAC 抑制剂联合用于癌症治疗的有希望的候选药物。

表征谱图